By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The stock prices of both Caliper Life Sciences and Illumina increased more than 100 percent in 2010, as the GWDN Index produced strong gains for the second year in a row amid a recovering broader market.

Overall, only nine of the 32 stocks listed in the GWDN Index below finished the year below their price at the end of 2009, with Vermillion and CombiMatrix dropping the most during the year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.